

Blueberries Medical Announces C\$1 Million Non-Brokered Private Placement

Blueberries secures C\$1.05M in private placement led by Terraflos to fund expansion and operations across Latin America.

TORONTO, ONTARIO, CANADA, March 25, 2025 /EINPresswire.com/ --

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) (the

"Company" or "Blueberries"), a Latin American licensed producer of medicinal cannabis and cannabis-derived products, is pleased to

announce a non-brokered private placement consisting of the sale of

96,064,935 common shares ("Common Shares") at a price of C\$0.011 per Common Share for aggregate gross proceeds of approximately C\$1.05 million (or approximately US\$740,000) (the "Offering"). The net proceeds from the sale of the Common Shares are expected to fund and expand operations, for general corporate and working capital purposes. The Offering is expected to close on or about March 25, 2025.

It is expected that the Offering will be led by Terraflos Inc. ("Terraflos"), a company with operations throughout Latin America founded and controlled by Facundo Garreton ("Mr. Garreton"), who serves as the Chairman, CEO, and a director of Blueberries. Terraflos is currently exploring various prospects in Argentina, Mexico, and Brazil and aims to expand its operations into those markets in the short term. The company's objective is to satisfy food and medicine needs in the near future using non-conventional methods, without exploiting natural resources as is common in current methodologies. In addition, Guillermo Rodriguez, a director of the Company, is also expected to participate in the Offering.

Early Warning Disclosure

Immediately prior to the Offering Mr. Garreton, directly and through Terraflos, owned 242,346,666 Common Shares, options exercisable into 5,049,500 Common Shares (the "Options"). If the Options were exercised in full, it would result in the issuance of 5,049,500



Blueberries
Medical Corp.

Common Shares to Mr. Garreton for aggregate holdings on an as converted basis of 247,396,166 Common Shares, representing, on a partially diluted basis, approximately 61.23% of the outstanding Common Shares prior to the Offering. Immediately following the Offering, Mr. Garreton owned on an as converted basis (assuming the exercise the Options, directly and through Terraflos: 313,461,101 Common Shares representing, on a partially diluted basis, approximately 62.67% of the outstanding Common Shares.

Mr. Garreton, through Terraflos, acquired the Common Shares for investment purposes, and he may, depending on market and other conditions, increase or decrease his beneficial ownership, control or direction over additional securities of the securities or otherwise. Other than as noted above and a right to a board seat for so long as Mr. Garreton holds at least 8% of the outstanding Common Shares on an as converted basis, Mr. Garreton does not have any plans related to any of the matters in the enumerated list in Item 5.1 of Form 62-103F1.

Mr. Garreton will prepare and file a report containing the information required by Form 62-103F1 - Required Disclosure under the Early Warning Requirements in connection with the matters referred to in this press release. Once filed, a copy of the early warning report will be available under the Company's issuer profile on SEDAR+ at www.sedarplus.ca.

Participation by Terraflos and Mr. Garreton in the Offering was considered a "related party transaction" pursuant to Multilateral Instrument 61-101 – Protection of Minority Security Holders in Special Transactions ("MI 61-101"). The Company was exempt from the requirements to obtain a formal valuation or minority shareholder approval in connection with Terraflos' and Mr. Garreton's participation in the Offering in reliance of sections 5.5(b) and 5.7(1)(b) of MI 61-101. A material change report was filed in connection with the participation of Terraflos and Mr. Garreton in the Offering less than 21 days in advance of the closing of the Offering, which the Company deemed reasonable in the circumstances so as to be able to avail itself of potential financing opportunities and complete the Offering in an expeditious manner.

Additional information about the Company is available at www.blueberriesmed.com. For more information, please contact:

Thomas Rodriguez Prats, Chief Financial Officer
trodriguez@blueberriesmed.com
Tel: +57 311 617 4246

Gustavo Gutierrez
Blueberries Medical Corp
+57 317 6674812
[email us here](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/796988714>
EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors

try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2025 Newsmatics Inc. All Right Reserved.